America Pouchitis Treatment Market Research Report: By Treatment (Antibiotics (Ciprofloxacin, Metronidazole, Rifaximin), Probiotics, and others (Budenoside, Immunosuppressive Therapy)), By End Users (Hospitals & Clinics, Institutes) – Forecast till 2023
Pouchitis is one of the most common complications of ileal pouch-anal anastomosis (IPAA) surgery and has a significant adverse impact on the quality of life. Pouchitis is an inflammation of the surgically constructed pouch. Various therapies are recommended for the treatment of pouchitis such as antibiotics, budesonide enemas, probiotics, probiotics, butyrate suppositories, bismuth enemas, and others.
The America Pouchitis Treatment Market is expected to grow at a CAGR of 8.34% during the forecast period 2017-2023.
Increasing need for ileal pouch-anal anastomosis procedure, long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs), rising prevalence of ulcerative colitis (UC), and increasing geriatric population are the key factors driving the pouchitis treatment market.
However, the side effects of the available treatment options and stringent FDA regulations may hinder the growth of the market to an extent. Till now not even a single drug is approved by the FDA for the treatment of pouchitis. However, few are in clinical trials waiting for approval such as Alicaforsen by Atlantic Healthcare plc.
Some of key the players in the Americas pouchitis treatment market are Pfizer, Abbott, Allergan Plc, Bayer, Takeda Pharmaceutical Company Limited, Alfa sigma, Atlantic Healthcare, Tillotts Pharma AG, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, B. Braun Medical Inc., Valeant Pharmaceuticals, Sucampo Pharmaceuticals, Ironwood Pharmaceuticals, Inc., Astellas Pharma Inc., Synergy Pharmaceuticals, Inc., Ardelyx, Inc., Sebela Pharmaceuticals, Probi, and others.
Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/5254 .
On the basis of region, the America pouchitis treatment market is segmented into North America, and South America. North America accounts for a major share owing to the rising cases of pouchitis, and high healthcare expenditure. People in this region are more inclined towards quality healthcare that leads to increase in the healthcare spending. Due to rising prevalence of pouchitis, various companies, private organizations, and government associations are also actively participating to improve the treatment options.
The Americas pouchitis market is driven by ongoing extensive research in the inflammatory bowel disease (IBD). The American Gastroenterological Association (AGA) has introduced several new research grants to support investigators studying inflammatory bowel disease (IBD) such as Takeda Pharmaceuticals research scholar awards in IBD, and Pfizer pilot research award in IBD.
1 Report Prologue
2 Market Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Data points received from the Doctors/ Gastrologist:
3.1.3 Data points received from the Manufacturer/ Pharmaceutical Companies:
Grab Attractive Discount @ https://www.marketresearchfuture.com/check-discount/5254 .
3.1.4 Data points received from Hospitals, Clinics:
3.1.5 Secondary Research Methodology
3.1.6 Market Share Analysis
3.1.7 Trade Analysis
3.1.8 Market Pricing Approach
4 Market Factor Analysis
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312